ОДЖЕР Курт Роберт (US),ПЕДДАРЕДДИГАРИ Виджай Гопал Редди (US)
申请号：
RU2015117483
公开号：
RU2015117483A
申请日:
2013.10.10
申请国别(地区):
RU
年份:
2016
代理人:
摘要：
1. A combination comprising: (i) a compound of structure (I): or a pharmaceutically acceptable salt thereof； and (ii) a compound of structure (II): or a pharmaceutically acceptable salt or solvate thereof. 2. A combination kit comprising the combination of claim 1 together with a pharmaceutically acceptable carrier or carriers. 3. The combination according to any one of paragraphs. 1 and 2, where the amount of the compound of structure (I) is an amount selected from 10 mg to 1000 mg, and this amount is administered once or twice a day, and the amount of the compound of structure (II) is an amount selected from from 0 , 1 mg to 5 mg, and the indicated amount is administered once a day. 4. The use of a combination according to any one of paragraphs. 1-3 for the manufacture of a medicament or medicaments for the treatment of cancer. 5. A method for treating cancer in a person in need thereof, which comprises in vivo administering a therapeutically effective amount of a combination of 2 - [(5-chloro-2 - {[3-methyl-1- (1-methylethyl) -1H-pyrazol-5-yl ] amino} -4-pyridinyl) amino] -N- (methyloxy) benzamide, or a pharmaceutically acceptable salt thereof, and N- {3- [3-cyclopropyl-5- (2-fluoro-4-iodophenylamino) -6.8 -dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydro-2H-pyrido [4,3-d] pyrimidin-1-yl] phenyl} acetamide, or a pharmaceutically acceptable salt or solvate thereof, such to a person where the combination is administered for a prescribed period and where the combination is administered in over a period of time. 6. The method of claim 5, wherein the amount of 2 - [(5-chloro-2 - {[3-methyl-1- (1-methylethyl) -1H-pyrazol-5-yl] amino} -4-pyridinyl) amino] - N- (methyloxy) benzamide, or a pharmaceutically acceptable salt thereof, is selected from about 20 mg to about 800 mg, and the indicated amount is administered once or twice daily and the amount of N- {3- [3-cyclopropyl-5- ( 2-fluoro-4-iodophenylamino) -6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydro-2H-pyrido [4,3-d] pyrimidin
